<DOC>
	<DOCNO>NCT00125307</DOCNO>
	<brief_summary>The investigator study efficacy safety tacrolimus treatment membranous nephritis secondary systemic lupus erythematosus .</brief_summary>
	<brief_title>Tacrolimus Treatment Systemic Lupus Erythematosus With Membranous Nephritis</brief_title>
	<detailed_description>Glomerulonephritis one major disease manifestation systemic lupus erythematosus ( SLE ) . The treatment membranous ( type V ) lupus nephritis , subset carry high morbidity , remain unsatisfactory . Recent study suggest immunosuppressive therapy target calcineurin pathway T-helper cell , example , tacrolimus , may effective treatment primary membranous nephropathy . The investigator plan conduct open-label single-arm study efficacy safety tacrolimus treatment membranous nephropathy secondary SLE . Twenty patient biopsy-proven membranous nephropathy secondary SLE recruit . They treat oral prednisolone tacrolimus 6 month , follow 6 month maintenance steroid alone . Proteinuria , renal function , clinical serologic lupus activity monitor . Complete remission define 24-hour urinary protein excretion le 0.5 gm/day . This study explore potential role tacrolimus treatment membranous lupus nephritis , usually resistant conventional therapy .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Fulfill revise American College Rheumatology criterion SLE Have biopsyproven membranous nephropathy secondary SLE Nephrotic syndrome proteinuria ( &gt; 3 g/day ) serum albumin &lt; 30 g/dl , without active urinary sediment despite steroid therapy ( without cytotoxic agent ) Age 18 informed consent Female patient childbearing age male patient agree maintain effective birth control practice study Patient abnormal liver function test Patient hepatitis B surface antigen hepatitis C antibody positive Patient diabetic Patient receive nonsteroidal antiinflammatory drug ( NSAIDs ) agent know influence urinary protein excretion Patient allergic intolerant macrolide antibiotic tacrolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>SLE</keyword>
	<keyword>glomerulonephritis</keyword>
	<keyword>immunosuppressive therapy</keyword>
	<keyword>type V ( membranous ) lupus nephritis</keyword>
</DOC>